|Bid||62.94 x 1300|
|Ask||62.86 x 1300|
|Day's Range||62.30 - 63.78|
|52 Week Range||57.17 - 74.12|
|Beta (5Y Monthly)||0.33|
|PE Ratio (TTM)||19.22|
|Earnings Date||Oct 26, 2022 - Oct 31, 2022|
|Forward Dividend & Yield||2.92 (4.65%)|
|Ex-Dividend Date||Sept 14, 2022|
|1y Target Est||70.78|
A look at the shareholders of Gilead Sciences, Inc. ( NASDAQ:GILD ) can tell us which group is most powerful. We can...
NORTHAMPTON, MA / ACCESSWIRE / September 23, 2022 / Gilead Sciences For Dr. Javier Cortes, being a breast cancer researcher isn't just a profession - it's a calling. As the head of the International Breast Cancer Center (IBCC) in Madrid and Barcelona, ...
Let's look at two biotech stocks that look attractive at current levels: AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD). AbbVie is one of the largest pharmaceutical companies around. Like other drugmakers, AbbVie benefits from the fact that doctors do not stop prescribing lifesaving drugs even during challenging economic times, nor do patients stop taking them.